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Available online 24 September 2016Spinal transient receptor potential ankyrin 1 (TRPA1) channel is associated with various pain hypersensitivity
conditions. Spinally, TRPA1 is expressed by central terminals of nociceptive nerve fibers and astrocytes. Among
potential endogenous agonists of TRPA1 is H2O2 generated by D-amino acid oxidase (DAAO) in astrocytes.
Here we studied whether prolonged block of the spinal TRPA1 or astrocytes starting at time of injury attenuates
development and/or maintenance of neuropathic hypersensitivity. Additionally, TRPA1 and DAAO mRNA were
determined in the dorsal root ganglion (DRG) and spinal dorsal horn (SDH). Experiments were performed in
rats with spared nerve injury (SNI) and chronic intrathecal catheter. Drugs were administered twice daily for
the first seven injury days or only once seven days after injury. Mechanical hypersensitivity was assessed with
monofilaments. Acute and prolonged treatment with Chembridge-5861528 (a TRPA1 antagonist),
carbenoxolone (an inhibitor of activated astrocytes), or gabapentin (a comparison drug) attenuated tactile
allodynia-like responses evoked by low (2 g) stimulus. However, antihypersensitivity effect of these compounds
was short of significance at a high (15 g) stimulus intensity. No preemptive effectswere observed. In healthy con-
trols, carbenoxolone failed to prevent hypersensitivity induced by spinal cinnamaldehyde, a TRPA1 agonist.
TRPA1 and DAAO mRNA in the DRG but not SDH were slightly increased in SNI, independent of drug treatment.
The results indicate that prolonged peri-injury block of spinal TRPA1 or inhibition of spinal astrocyte activation
attenuates maintenance but not development of mechanical (tactile allodynia-like) hypersensitivity after
nerve injury.






Spinal cord dorsal horn
TRPA11. Introduction
Transient receptor potential ankyrin 1 (TRPA1) is a calcium-perme-
able nonselective cation channel. In the nervous system, it is expressed
on a subpopulation of nociceptive primary afferent nerve fibers (Story
et al., 2003). On their peripheral nerve endings, TRPA1 is involved in
transduction of harmful signals into electric signals and on their centralsal root ganglion; ROS, reactive
receptor potential ankyrin 1.
Pharmacy, Shanghai Jiao Tong
iology, Faculty ofMedicine, POB
ntti.pertovaara@helsinki.fiendingswithin the spinal dorsal horn TRPA1 is involved in amplification
of glutamatergic transmission (see for review e.g., Andrade et al., 2012).
Another cell type in the nervous system expressing TRPA1 is astrocyte
onwhich TRPA1 contributes to regulation of the inhibitory synapse effi-
cacy in adjacent neurons (Shigetomi et al., 2011). Moreover, oligoden-
drocytes in the nervous system were recently shown to express
TRPA1 (Hamilton et al., 2016).
Nerve injuries may cause long-lasting pain accompanied by hyper-
sensitivity particularly to mechanical stimulation and cooling. There is
earlier evidence indicating that nerve injury-induced (neuropathic)
pain is at least partly mediated by TRPA1. This is indicated by the find-
ings that systemic block of TRPA1 genetically or pharmacologically sup-
pressed pain hypersensitivity in animals with a traumatic, chemical or
metabolic injury of peripheral nerves (e.g., del Camino et al., 2010; Eid
et al., 2008; Obata et al., 2005; Wei et al., 2009, 2012). Suppression of
neuropathic pain induced by systemically administered TRPA1
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TRPA1 has proved effective in attenuating hypersensitivity in experi-
mental models of neuropathy (Wei et al., 2010a, 2011).
Previous pharmacological studies demonstrating the
antihypersensitivity effect of spinal TRPA1 antagonists in chronic neuro-
pathic pain models were performed following the development of ful-
minant neuropathy and using acute single-dose treatments. This
leaves open whether a TRPA1 antagonist administered spinally at the
time of injury, e.g. when performing an elective operation in the clinic
that potentially causes nerve damage, and continuation of the treatment
for several days thereafter effectively attenuates the development and/
ormaintenance of pain hypersensitivity. Therefore, we assessedwheth-
er twice daily spinal treatment with a selective TRPA1 antagonist
starting at the time of nerve injury and continuing for aweek attenuates
the development and maintenance of hypersensitivity. Moreover, acti-
vation of spinal astrocytes has been associated with pain hypersensitiv-
ity (Hansson, 2010). Astrocytes express TRPA1 (Shigetomi et al., 2011)
and their activation leads to increased spinal level of astroglial D-
amino-acid oxidase (DAAO) that generates H2O2 (Zhao et al., 2010),
an established TRPA1 agonist (Andersson et al., 2008). To assess the po-
tential role of spinal astrocytes in the TRPA1 antagonist-induced
antihypersensitivity effect, we also assessedmechanical hypersensitivi-
ty following prolonged treatment of nerve-injured animals with spinal-
ly administered carbenoxolone, a gap junction blocker that inhibits
activation of astrocytes.
It was hypothesized that if prolonged blocking of spinal TRPA1 or as-
trocytes during thefirst injury days prevents the development of neuro-
pathic hypersensitivity, then the baseline hypersensitivity should be
attenuated (i.e., attenuation of hypersensitivity at a time point when
the pharmacological effect of the studied drug was over). On the other
hand, by testing the acute antihypersensitivity effect of the studied
compounds after a prolonged treatmentwe expected to reveal whether
the studied drugs attenuate maintenance of neuropathic hypersensitiv-
ity as effectively after prolonged as acute single treatment.
For additional information about the potential interaction of astro-
cytes and TRPA1, we studied whether carbenoxolone attenuates hyper-
sensitivity induced by spinal administration of cinnamaldehyde, a
selective TRPA1 agonist, in healthy controls. Gabapentin that has been
widely used in the treatment of neuropathic pain (Finnerup et al.,
2015) was the comparison drug. We also determined TRPA1 and
DAAO mRNA in the dorsal root ganglion (DRG) and the spinal dorsal
horn (SDH) to find out whether nerve injury or the currently used
drug treatments are associated with upregulations of TRPA1 or DAAO
mRNA.
2. Materials and methods
2.1. Experimental animals
The experiments were performed in 55 adult, male Hannover-
Wistar (HW) rats (weight: 150–200 g; CAS, Shanghai, China). None of
the animals died before the completion of the behavioral experiments.
Experiments were approved by the Science and Technology Commis-
sion of Shanghai Municipality (permission number SYXK 2012-0017)
and all experimental procedures are in compliancewith theNational In-
stitutes of Health Guide for Care and Use of Laboratory Animals (Publi-
cation No. 85-23, revised 1985). All efforts were made to minimize
animal suffering and to use only the number of animals necessary to
produce reliable scientific data.
2.2. Techniques for intrathecal catheter installation and drug
administration
For intrathecal (i.t.) drug injections a catheter (PE-10) was adminis-
tered on day 0 (D0) into the lumbar level of the spinal cord under sodi-
um pentobarbital anesthesia (60 mg/kg i.p.) as described in detailelsewhere (Størkson et al., 1996). For i.t. administration, the drugs
were microinjected with a 50 μl syringe in a volume of 5 μl followed
by a saline flush in a volume of 20 μl. I.t. administrations of drugs were
performed in awake animals that were well-habituated to handling.
During i.t. drug administration, the animal was gently restrained by
one hand of the experimenter, while the other hand was used for drug
injection. The animals expressed no obvious sign of discomfort due to
restraint or i.t. injections.
2.3. Techniques for producing neuropathy
There are a number of surgically induced models of peripheral neu-
ropathy (Honoré et al., 2011), of which the spared nerve injury model
(SNI; Decosterd and Woolf, 2000) was adopted. Prior to surgery, the
rat was anesthetized with sodium pentobarbital administered intraper-
itoneally at the dose of 60mg/kg. Further doses of sodium pentobarbital
were given at the dose of 15–20 mg/kg as needed to keep the depth of
anesthesia deep enough so that the animal did not react to noxious
stimulation. SNI surgerywas performed onD0 in the same session as in-
stallation of i.t. catheter.
In the SNI operation, an incisionwasmade into the skin on the later-
al surface of the left thigh, followed by a section through the biceps
femoris muscle to expose the sciatic nerve and its terminal branches:
the sural, common peroneal and tibial nerves. The common peroneal
and tibial nerveswere then tightly ligatedwith 4–0 silk, sectioned distal
to the ligation and 3–4mmof the distal nerve stump removed. The sural
nerve was left intact and care was exercised not to stretch it. For com-
parison, one group of sham-operated animals was studied. Sham oper-
ation was performed identically as the operation for inducing SNI,
except that the common peroneal and tibial nerves were left intact.
After the operations, the muscle and skin were sutured, and the rats
weremoved to their individual home cages for recovery. Since the stud-
ied compoundswere presumed tohave analgesic properties and thepo-
tential analgesic efficacy of the studied compounds given peri- vs only
postoperatively was among the study questions, no additional analgesic
treatment were in the study protocol, unless the animals showed signs
of suffering or spontaneous pain. In the latter case, the animal was eu-
thanized before completing the experiment, which, however, was not
needed in the present sample of animals.
2.4. Behavioral testing
Since mechanical rather than heat hypersensitivity is a frequent
problem in patients with peripheral neuropathy (Scadding and
Koltzenburg, 2006), the focus was on mechanically evoked pain behav-
ior. Furthermore, central mechanisms that were studied in the present
experiments play an important role in hypersensitivity to mechanical
rather than heat stimulation (Treede et al., 1992). Before thefirst assess-
ment of pain behavior on D0, the animals were habituated to the exper-
imental conditions at least for /day for two days. To assess mechanical
hypersensitivity, the frequency of thewithdrawal response to the appli-
cation of monofilaments (von Frey hairs) to the sural nerve area in the
hind paw was examined while the animal was standing on a metal
grid that was covered by a plastic cage. A series of ten hairs with forces
varying from 0.4 g to 60 g (North Coast Medical, Inc., Morgan Hill, CA)
were applied five times each at a frequency of approximately of
0.5 Hz. Hairs were tested in ascending order of force. A visible lifting
of the stimulated hind limb was considered a withdrawal response. If
the rat failed to withdraw to any of the five presentations of a monofil-
ament, the response rate for the studied force level was 0%. If the rat
withdrew every time the monofilament was applied to the paw, the re-
sponse rate for the studied force level was 100%. Thus, an increase in the
response rate represents facilitation of mechanical stimulus-evoked
pain behavior (hypersensitivity). In this study, results on testing me-
chanical sensitivity are reported at two different test stimulus intensi-
ties: a low test stimulus force (2 g) that activates only low-threshold
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co-activation of nociceptors (Leem et al., 1993).
Behavioral testing of mechanical hypersensitivity was performed on
D0 (before induction of anesthesia for the installation of i.t. catheter and
SNI surgery) and on D7, the last day of the experiment (Fig. 1). On D7,
behavioral assessment of hypersensitivity was performed once before
i.t. administration of the last drug/vehicle dose. This pre-drug assess-
ment on D7, at a time point when the acute drug effect of the previous
drug dose was over, allowed determining the potential effect of the
prolonged twice daily drug treatment on the development of baseline
hypersensitivity. The pre-drug assessment of hypersensitivity on D7
was followed by the assessment of the drug-induced acute
antihypersensitivity effect 15, 30 and 60 min after the last drug/vehicle
dose (Fig. 1).
2.5. Real-time quantitative polymerase chain reaction (RT qPCR)
Rat SDHs (L3-L5) and DRGs ipsilateral to injury were collected and
homogenized using electronic microhomogenizer at 4000 rmp for 10 s
in TRIzol (Invitrogen, Grand Island, NY, USA) on ice. Total RNAof the spi-
nal lumbar enlargementswas extracted and purified by use of TRIzol re-
agent. The cDNAwas prepared from 1 μg of total RNA by using ReverTra
Ace qPCR RT-Kit (Toyobo Co. Ltd., Osaka, Japan). Real-time quantitative
PCR was performed on a Mastercycler ep realplex (Eppendorf, Ham-
burg, Germany) using Realmaster Mix (SYBR Green I) and synthetic
primers. The sequences of primers were following: DAAO: 5′-CCC TTT
CTG GAA AAG CAC AG-3′(forward), 5′-CTC CTC TCA CCA CCT CTT CG-
3′(reverse) (Zhao et al., 2010); TRPA 1: 5′-CTC AGG TTC AAT GTG TCC
GTTC-3′(forward), 5′-GTG CTG TGT TCC CTT CATC-3′(reverse) (Du et
al., 2007); GAPDH: 5′-CCA AGG TCA TCCATG ACA AC-3′ (forward), 5′-
TCC ACA GTC TTC TGA GTGGC-3′ (reverse) (Vahl et al., 2007). The
2−ΔΔCt method was used to calculate the relative expression after nor-
malization to the internal control gene GAPDH (Zhao et al., 2010).
2.6. Drugs
Chembridge-5861528, TRPA1 antagonist (Koivisto and Pertovaara,
2015), was obtained from ChemBridge Corp. (San Diego, CA).
Carbenoxolone (a gap junction decoupler), cinnamaldehyde (a TRPA1
agonist) and gabapentin (a widely used analgesic compound against
neuropathic pain) were purchased from Sigma-Aldrich (St.Louis, MO).
Vehicle consisted of polyethylene glycol (75%) and physiological saline
(25%). All compounds were administered intrathecally (i.t.) to the lum-
bar level of the spinal cord. Drug doses were chosen based on earlier
studies assessing the antihypersensitivity effect of spinally adminis-
tered Chembridge-5861528 (e.g., Wei et al. 2010a & 2011) and
carbenoxolone (Wei et al., 2010b), or hypersensitivity effect of
cinnamaldehyde (Wei et al., 2011). When considering the dose of
Chembridge-5861528, it should be noted that due to binding to brain
proteins, only about 2.3% of Chembridge-5861528 is free in the brain
(Wei et al., 2012). The dose of gabapentin, the comparison drug, was
50 μg that has been shown to be the ED50 value of intrathecally admin-
istered gabapentin against tactile-allodynia like symptoms in rodents
(Cheng et al., 2000).Fig. 1.Course of the study.D0–D7 representDay 0–Day 7. Triangleswith letterm represent time
last spinal drug/vehicle administration. The circlewith letters i.t. represents time point for instal
ligation or sham operation. Broken arrows represent time points for repeated spinal drug/
monofilament test) when animals were euthanized.2.7. Course of the study
There were ten experimental groups, in all of which animals were
equipped with a chronic catheter for i.t. drug deliveries (see Table 1
for the groups i–viii). The ten experimental groups were: i) CHEM D0–
D7 group of SNI animals, in which Chembridge-5861528 was adminis-
tered twice daily fourteen times at the dose of 10 μg (n = 6). ii)
CHEM D7 group of SNI animals, in which vehicle was administered
twice daily thirteen times, while the last (14th) i.t. treatment on D7
was Chembridge-5861528 at the dose of 10 μg (n = 6). iii)
Carbenoxolone D0–D7 group of SNI animals, in which carbenoxolone
was administered twice daily fourteen times at the dose of 10 μg
(n = 6). iv) Carbenoxolone D7 group of SNI animals, in which vehicle
was administered twice daily thirteen times, while the last i.t. treatment
on D7 was 10 μg of carbenoxolone (n = 5). v) Vehicle group of SNI an-
imals, in which vehicle was administered twice daily fourteen times
(n= 5). vi) Sham-operated control group, in which vehicle was admin-
istered twice daily fourteen times (n=5). vii) SNI animals treated twice
daily, a total of 14 times, with 50 μg of gabapentin that served as a com-
parison drug that is widely used in the treatment of neuropathic pain in
the clinic (n = 5), viii) SNI animals treated once with 50 μg of
gabapentin (n=5). ix) healthy control animals treatedwith a combina-
tion of vehicle followed 15 min later by 10 μg of cinnamaldehyde, a
TRPA1 agonist (n = 6), x) healthy control animals treated with a com-
bination of 10 μg of carbenoxolone followed 15 min later by 10 μg of
cinnamaldehyde (n = 6).
Experiment startedwith a two-day habituation of the animals to the
experimental conditions (handling, gentle restraint for i.t. drug delivery,
and testing of the withdrawal threshold). On D0, first the preoperative
sensitivity to mechanical stimulation was determined. Then, the animal
was anesthetized for the installation of i.t. catheter and the SNI or sham
operation in the same session. In groups i–viii, the first i.t. drug/vehicle
delivery was performed on D0 when the animal was under anesthesia
(immediately after installation of the i.t. catheter and 15 min before
nerve injury or sham operation). The rationale for administering the
first i.t. drug/vehicle dose about 15 min before nerve ligation in groups
i–viii was to allow assessing potential pre-emptive effects of the studied
compounds. Namely, earlier it was shown that intraperitoneal adminis-
tration of an N-methyl-D-aspartate receptor antagonist 15 min before
nerve ligation, in contrast to 15min after nerve ligation, produced a sig-
nificant pre-emptive effect as indicated by a reduction in hypersensitiv-
ity that lasted at least up to two weeks in spinal nerve-ligated animals
(Wei and Pertovaara, 1999). After procedures performed onD0, animals
in groups i–viii were allowed to recover from anesthesia and then, drug
or vehicle was delivered twice daily on D1–D6 (Fig. 1). However, in
healthy control groups ix–x, the first and only i.t. treatment was per-
formed on D7.
On D7, themonofilament test was performed in all animals once be-
fore the last injection of the studied compound (for assessment of base-
line hypersensitivity) and then 15, 30, and 60 min after i.t.
administration of the compound (for assessment of acute
antihypersensitivity effect of the studied drugs). Each animal participat-
ed only in one of the experimental conditions.
The animals were euthanized about 30min after performing the last
monofilament test on D7, and the L5–L6 DRGs and the SDH ipsilateral topoints formonofilament testing; 15′-60′ onD7 indicate time of testing inminutes after the
lation of intrathecal catheter, and the circlewith letters SNI represents time point for nerve
vehicle applications. The cross on D7 represents the time point (30 min after the last
Table 1
Drug treatment procedures in experimental groups i–viii.
Group # Twice daily i.t. treatment on
D0–D6
Last i.t. treatment on D7
i CHEM D0–D7 Chembridge-5861528 10 μg Chembridge-5861528
10 μg




Carbenoxolone 10 μg Carbenoxolone 10 μg
iv Carbenoxolone D7 Vehicle Carbenoxolone 10 μg
v Vehicle D0–D7 Vehicle Vehicle
vi Sham Vehicle Vehicle
vii Gabapentin D0–D7 Gabapentin 50 μg Gabapentin 50 μg
viii Gabapentin D7 Vehicle Gabapentin 50 μg
D0–D7 refer to postinjury days 0–day 7.
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described in Section 2.5. Due to various technical errors, DRG or SDH
sampling was not successful in all cases and therefore, in some groups
the number of DRG or SDH samples is smaller than the number of be-
haviorally tested animals in the same experimental condition.
2.8. Statistical analysis of data
Since the response rate to monofilament stimulation in some test
conditions reached the floor (0%) or the ceiling (100%), statistical anal-
yses of the data on mechanical sensitivity were performed using non-
parametric Kruskal-Wallis or Friedman's test followed by Dunn's test
(comparisons of three or more groups), or by using Mann-Whitney U
test (comparison of two groups). mRNA data was normally distributed
in all mRNA data groups in which normality could be tested using Kol-
mogorov-Smirnov test. However, in some mRNA data groups the num-
ber of samples was too low (n b 5) to allow normality test. Therefore,
statistical analysis of all mRNA data was performed using non-paramet-
ric Kruskal-Wallis test followed by Dunn's test. P b 0.05 was considered
to represent a significant difference.
3. Results
3.1. Induction of mechanical pain hypersensitivity by SNI
Installation of i.t. catheter, shamoperation and the seven-day vehicle
treatment had no long-term influence on pain behavior as indicated by
comparison of monofilament-evoked responses at an innocuous stimu-
lus force of 2 g or at a noxious stimulus force of 15 g in vehicle-treated
sham controls preoperatively on day 0 versus the seventh vehicle treat-
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Fig. 2. A) Mechanical sensitivity in sham-operated vehicle-treated control animals preopera
sensitivity in animals with spared nerve injury (SNI) and sham operation (Sham) after a seve
repeated monofilament stimulation at an innocuous test stimulus force of 2 g and a noxious t
showmedians, the boxes extend from the 25th to the 75th percentile, and thewhiskers extendhypersensitivity effect as revealed by comparison of monofilament-
evoked responses in sham controls versus SNI animals at an innocuous
force of 2 g or a noxious force of 15 g (Fig. 2B).
3.2. Antihypersensitivity effect induced by i.t. administration of
Chembridge-5861528
To assess time-course of the antihypersensitivity effect induced by
acute pharmacological blocking of the spinal TRPA1, mechanical hyper-
sensitivity was assessed on postoperative day 7 (D7) at various time
points following administration of a single dose of Chembridge-
5861528 (CHEM; a TRPA1 antagonist) in the group treated twice daily
for six previous days with CHEM (group CHEM D0–D7). CHEM treat-
ment had a significant acute effect on mechanical hypersensitivity
(main effect of time in the CHEM D0–D7 group: Fr = 11.9, P =
0.0026), whereas in the group pretreated twice daily for the previous
six days with vehicle, vehicle on the seventh treatment day failed to
have an acute influence on mechanical hypersensitivity (main effect of
time in the Veh group: Fr = 3.0; Fig. 3A). Post hoc testing indicated
that the mechanical antihypersensitivity effect induced by CHEM was
significant 30 min after administration of CHEM, and the
antihypersensitivity effect was reduced to a non-significant level
60 min after CHEM administration (Fig. 3A).
To assess whether the seven-day treatment with twice daily admin-
istration of CHEM (10 μg) influences the acute antihypersensitivity ef-
fect of CHEM, the mechanical antihypersensitivity effect induced by
CHEM (10 μg) was assessed in SNI groups treated the preceding seven
days twice daily with vehicle (CHEM D7 group) or with CHEM (CHEM
D0–D7 group). A reference group of SNI animals received vehicle both
at the time of testing and twice daily during the preceding seven days.
These assessments were performed on D7 before and at 15 min,
30min and 60min after drug/vehicle administration. Responses evoked
by a low (2 g) and a high (15 g) test stimulus force (15 g) were evaluat-
ed separately.
On the seventh treatment day, the antihypersensitivity effects in the
three drug treatment groups (CHEM D7, CHEM D0–D7, Veh) were sig-
nificantly different when assessed at a low test stimulus force of 2 g
(KW = 14.3, P = 0.0002; Fig. 3B). Post hoc testing indicated that on
the seventh treatment day, the acute antihypersensitivity effect induced
by CHEM was significant both in the CHEM D7 and the CHEM D0–D7
group when compared with the effect of saline administration in the
Veh group (Fig. 3B). Moreover, post hoc testing indicated that the base-
line hypersensitivity of SNI animals just before the last treatment dose
on the seventh treatment day was not significantly different among
the treatment groups (KW = 1.4; not shown).
When the antihypersensitivity effect induced by CHEMwas assessed
on the seventh treatment day using a test stimulus force of 15 g, the dif-
























tively on day 0 (D0) and postoperatively on day 7 (D7). B) Comparison of mechanical
n-day i.t. treatment with vehicle. The graphs show the limb withdrawal response rate to
est stimulus force of 15 g. Increase in the response rate indicates hypersensitivity. Graphs
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Fig. 3. Influence by prolonged intrathecal treatment with 10 μg of Chembridge-5861528 (CHEM; TRPA1 antagonist) or vehicle (Veh) on mechanical hypersensitivity in a spared nerve
injury model of neuropathy. A) Time-course of the effect at a test stimulus force of 2 g. B) Response rate change before versus 30 min after drug administration tested at a stimulus
force of 2 g. C) Response rate change before and 30 min after drug administration tested at a stimulus force of 15 g. In A, higher the response rate, stronger the hypersensitivity. In B
and C, 0% represents the response rate before drug administration and response rate values b0% represent drug-induced antihypersensitivity effect. In group D0–D7, the animals
received twice daily 10 μg of Chembridge-5861528 for seven days. In group D7, animals received twice daily vehicle, except that the last injection on day 7 was 10 μg of Chembridge-
5861528. In Veh group, animals received twice daily vehicle for seven days. In all groups, hypersensitivity measurements were performed on the seventh treatment day (D7). Graphs
show medians, the boxes extend from the 25th to the 75th percentile, and the whiskers extend from the smallest to the largest value (n = 6, except that nVeh = 5). *P b 0.05,
**P b 0.01 (Dunn's test; reference: the corresponding Pre-value in A, and Veh-value in B and C, unless defined otherwise).
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3C). On the seventh treatment day, the baseline (pre-drug) response
rate to a test stimulus force of 15 g was not significantly different
among the treatment groups (KW= 5.3; not shown).
3.3. Antihypersensitivity effect induced by i.t. administration of
carbenoxolone
To assess time-course of the antihypersensitivity effect induced by
acute pharmacological decoupling of gap junctions in the spinal dorsal
horn (SDH), mechanical hypersensitivity was assessed at a force of 2 g
on D7 at various time points following i.t. administration of 10 μg of
carbenoxolone (a gap junction decoupler) in SNI animals that received
the previous six days twice daily carbenoxolone (carbenoxolone D0–
D7 group). Carbenoxolone treatment had a significant acute effect on
hypersensitivity (main effect of time in the carbenoxolone D0–D7
group: Fr = 14.3, P = 0.0004; Fig. 4A), while vehicle treatment failed
to influence hypersensitivity in the Veh group (main effect of time:
Fr = 3). Post hoc tests indicated that carbenoxolone (10 μg i.t.) pro-
duced a significant mechanical antihypersensitivity effect only 15 min
after its application (Fig. 4A). In further analyses, carbenoxolone-in-
duced effects were assessed 15 min after its i.t. administration.
To assess whether the seven-day treatment with twice
daily spinal administration of carbenoxolone (10 μg) influences
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Fig. 4. Influence by prolonged intrathecal treatmentwith 10 μg of carbenoxolone (gap junction
of neuropathy. A) Time-course of the effect at a test stimulus force of 2 g. B) Response rate chang
rate change before versus 15 min after drug administration at a test stimulus force of 15 g. In
response rate before drug administration and response rate values b0% represent drug-induc
carbenoxolone for seven days. In group D7, animals received twice daily vehicle, except that th
twice daily vehicle for seven days. In all groups, hypersensitivity was assessed on the seventh
percentile, and the whiskers extend from the smallest to the largest value (nD1–D7 = 6, nD7 =
corresponding Veh value in B).antihypersensitivity effect induced by carbenoxolone (10 μg)
was assessed in SNI groups treated the preceding seven days
twice daily with vehicle (carbenoxolone D7 group) or with
carbenoxolone (carbenoxolone D0–D7 group). A reference
group of SNI animals received vehicle at the test day as well
as during the preceding seven days (Veh group).
Acute antihypersensitivity effect assessed at an innocuous stimulus
force of 2 g on the seventh treatment day varied significantly among
the three treatment groups (KW = 8.2, P = 0.011; Fig. 4B). Post hoc
testing indicated that when compared with the vehicle treatment
group, acute carbenoxolone treatment produced a significant
antihypersensitivity effect in the carbenoxolone D0–D7 group but not
in the carbenoxolone D7 group (Fig. 4B). On the seventh treatment
day, the baseline (pre-drug) response rate to a test stimulus force of
2 g was not significantly different among the treatment groups
(KW = 2.8; not shown).
Acute effects of carbenoxolone/vehicle on mechanical hypersensi-
tivity assessed at a noxious stimulus force of 15 g on the seventh treat-
ment day were not significantly different among the three treatment
groups (KW = 3.0; Fig. 4C); i.e.; carbenoxolone failed to produce an
acute antihypersensitivity effect at test force 15 g either in the
carbenoxolone D7 or carbenoxolone D0–D7 group. On the seventh
treatment day, the baseline (pre-drug) response rate to a test stimulus
force of 15 g was not significantly different among the three treatment
groups (KW = 4.2; not shown).7 0-D7
tivity effect at 2 g
**
arbenoxolone





















decoupler) or vehicle (Veh) onmechanical hypersensitivity in a spared nerve injurymodel
e before versus 15min after drug administration at a test stimulus force of 2 g. C) Response
A, higher the response rate, stronger the hypersensitivity. In B and C, 0% represents the
ed antihypersensitivity effect. In group D0–D7, the animals received twice daily 10 μg of
e last injection on day 7 was 10 μg of carbenoxolone. In the Veh group, animals received
treatment day (D7). Graphs show medians, the boxes extend from the 25th to the 75th
5, nVeh = 5). *P b 0.05 (Dunn's test; reference: the corresponding Pre-value in A, and the
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carbenoxolone in healthy controls
To study further whether a possible interaction of astrocytes with
TRPA1 might contribute to the present results, we induced mechanical
hypersensitivity in healthy control animals by administering i.t. 10 μg
of cinnamaldehyde, a TRPA1 agonist, and attempted to prevent the
cinnamaldehyde-induced hypersensitivity by pretreating the animal
with 10 μg of carbenoxolone. In vehicle pretreated animals,
cinnamaldehyde increased the median withdrawal response rate
evoked by an innocuous stimulus force of 2 g from 0% to 20%, and that
evoked by a noxious stimulus force of 15 g from 70% to 100% (n = 6).
I.t. pretreatment with 10 μg of carbenoxolone failed to attenuate the
cinnamaldehyde-induced hypersensitivity at an innocuous (U = 8;
Fig. 5A) or a noxious stimulus range (U = 14.5; Fig. 5B).
3.4. Antihypersensitivity effect induced by i.t. administration of gabapentin
For comparison, antihypersensitivity effect induced by gabapentin, a
clinically used analgesic compound, was assessed. Mechanical hyper-
sensitivity determined at an innocuous force of 2 g was significantly in-
fluenced by gabapentin/vehicle treatments (KW = 12.3, P = 0.0002;
Fig. 5C). Post hoc testing indicated that 50 μg of gabapentin produced
a significant antihypersensitivity effect as assessed at the innocuous
force of 2 g independent whether it had been administered twice














































Fig. 5. Attempt to prevent TRPA1 agonist-induced hypersensitivity by pretreatment with ca
gabapentin in the spared nerve injury model of neuropathy (C, D). Change in response rate b
noxious force of 15 g (B and D). Testing performed in unoperated controls (A and B) or
corresponding pre-drug value, response rate value N0% represent drug-induced increase in h
animals received intrathecally vehicle (Veh) or carbenoxolone (Cbx, a gap junction decoup
agonist; 10 μg) 2 min before testing. In C and D, the animals in group D0–D7 received twice d
once intrathecally 50 μg of gabapentin at postoperative day 7, and in the Veh group animals r
assessed on the seventh treatment day (D7). Graphs show medians, the boxes extend from t
value (n = 5). *P b 0.05, **P b 0.01 (Dunn's test; reference: the corresponding Veh value).once after a seven-day vehicle treatment period (groups gabapentin
D0–D7 and gabapentin D7, respectively; Fig. 5C). However, when the
antihypersensitivity effect of gabapentin was assessed at the noxious
stimulus force of 15 g, gabapentin/vehicle treatments failed to have a
significant acute effect on hypersensitivity (KW = 3.3; Fig. 5D).
3.4.1. Expression of TRPA1 mRNA in animals treated with Chembridge-
5861528
The assessment of the dorsal root ganglion (DRG) in CHEM/vehicle-
treated SNI animals and sham-operated controls indicated that the ex-
pression of TRPA1 mRNA was influenced by the experimental condi-
tions (KW = 11.8, P = 0.008). Post hoc tests indicated that when
compared with the DRG of sham-operated animals, the expression of
TRPA1 mRNA was increased in the DRG of SNI animals treated for
seven days with vehicle or with CHEM (CHEM D0–D7 group), while
there was no significant difference of the TRPA1 mRNA expression in
the DRG among the three different treatment groups of SNI animals
(Vehicle, CHEM D7, CHEM D0–D7; Fig. 6A). In the spinal dorsal horn
(SDH), the expression of TRPA1mRNAwas not influenced by the exper-
imental conditions (KW = 0.4, P = 0.9; Fig. 6B).
3.4.2. Expression of TRPA1 mRNA in animals treated with carbenoxolone
The assessment of theDRG in carbenoxolone/vehicle-treated SNI an-
imals and sham-operated controls indicated that the expression of












































rbenoxolone in healthy controls (A, B), and the influence by prolonged treatment with
efore versus after drug administrations tested at an innocuous force of 2 g (A and C) or a
in animals with a spared nerve injury (C and D). Response rate 0% represents the
ypersensitivity, whereas values b0% represent an antihypersensitivity effect. In A and B,
ler; 10 μg) 15 min before post-drug testing followed by cinnamaldehyde (CA, a TRPA1
aily intrathecally 50 μg of gabapentin for seven days, while in group D7 animals received
eceived twice daily intrathecally vehicle for seven days. In C and D, hypersensitivity was
he 25th to the 75th percentile, and the whiskers extend from the smallest to the largest





































































































Fig. 6. Expression of TRPA1mRNA in the dorsal root ganglion (DRG; A & C) and the spinal dorsal horn (SDH; B & D) following prolonged intrathecal treatment with 10 μg of Chembridge-
5861528 (CHEM; A & B), carbenoxolone (C & D) or vehicle (Veh; A–D). In groups D0–D7, the animals received twice daily 10 μg of Chembridge-5861528 or carbenoxolone for seven days.
In group D7, animals received twice daily vehicle, except that the last injection on day 7 was 10 μg of Chembridge-5861528 or carbenoxolone. In the Veh group, animals received twice
daily vehicle for seven days. The samples were taken about 90 min after the last drug injection. The dotted horizontal lines (1.0) represent mRNA expression in vehicle-treated sham-
operated control animals. Graphs show medians, the boxes extend from the 25th to the 75th percentile, and the whiskers extend from the smallest to the largest value. In each group,
n = 4–6. *P b 0.05, **P b 0.01 (Dunn's test; reference: the corresponding value in the sham control group).
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with the DRG of sham-operated controls, the expression of TRPA1
mRNA was increased in the vehicle-treated SNI group, while there
were no significant differences among vehicle- and carbenoxolone-
treated SNI groups (Fig. 6C). In the SDH, the expression of TRPA1
mRNA was not influenced by the experimental conditions (KW = 3.9,
P = 0.3; Fig. 6 D).
3.4.3. Expression of DAAO mRNA in animals treated with Chembridge-
5861528
The assessment of the DRG in CHEM/vehicle-treated SNI animals
and shamcontrols indicated that the expression of DAAOmRNAwas in-
fluenced by the experimental conditions (KW = 15.0, P = 0.0018; Fig.
7A). Post hoc tests indicated that when compared with the DRG of
sham controls, the expression of DAAO mRNA was increased in both
of the CHEM-treated SNI groups (D7 and D0–D7), while there were no
significant differences in DAAO mRNA expression among vehicle- and
CHEM-treated SNI groups (Fig. 7A). In the SDH, the expression of
DAAO mRNA was not influenced by the experimental conditions
(KW = 4.2, P = 0.24; Fig. 7B).
3.4.4. Expression of DAAO mRNA in animals treated with carbenoxolone
The assessment of theDRG in carbenoxolone/vehicle-treated SNI an-
imals and sham controls indicated that the expression of DAAO mRNA
was influenced by the experimental conditions (KW = 11.9, P =0.0011; Fig. 7C). Post hoc tests indicated that when compared with
the DRG of sham controls, the expression of DAAOmRNAwas increased
in one of the carbenoxolone-treated SNI groups (D7 group), while there
were no significant differences in DAAOmRNA expression among vehi-
cle- and carbenoxolone-treated SNI groups (Fig. 7C). In the SDH, the ex-
pression of DAAO mRNA was not influenced by the experimental
conditions (KW = 1.3, P = 0.7; Fig. 7D).
4. Discussion
4.1. Antihypersensitivity effect induced by spinal administration of a TRPA1
antagonist or a gap junction decoupler
Acute spinal administration of a selective TRPA1 antagonist attenu-
ated maintenance of neuropathic pain hypersensitivity in the SNI
model of neuropathy, which finding is in line with earlier results in spi-
nal nerve ligation- and diabetes-induced models of experimental neu-
ropathy (Wei et al. 2010a, 2011). Antihypersensitivity effect induced
by acute pharmacological blocking of the spinal TRPA1 has earlier
been shown also in various other models of pain hypersensitivity,
such as that induced by persistent inflammation induced by Complete
Freund's Adjuvant (da Costa et al., 2010), skin incision (Wei et al.,
2012), neurogenic inflammation (Wei et al., 2010a), spinal nerve liga-
tion, and sleep-deprivation (Wei et al., 2011). Additionally, spinal
TRPA1 may contribute to nociception also in physiological conditions


































































































Fig. 7. Expression of D-amino acid oxidase (DAAO)mRNA in the dorsal root ganglion (DRG; A & C) and the spinal dorsal horn (SDH; B & D) following prolonged intrathecal treatmentwith
10 μg of Chembridge-5861528 (CHEM; A & B), carbenoxolone (C & D) or vehicle (Veh; A–D). In group D0–D7, the animals received twice daily 10 μg of Chembridge-5861528 or
carbenoxolone for seven days. In group D7, animals received twice daily vehicle, except that the last injection on day 7 was 10 μg of Chembridge-5861528 or carbenoxolone. In the
Veh group, animals received twice daily vehicle for seven days. The samples were taken about 90 min after the last drug injection. The dotted horizontal lines (1.0) represent mRNA
expression in vehicle-treated sham-operated control animals. Graphs show medians, the boxes extend from the 25th to the 75th percentile, and the whiskers extend from the smallest
to the largest value. In each group, n = 4–6. *P b 0.05, **P b 0.01 (Dunn's test; reference: unless specified, the corresponding value in sham controls).
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earlier findings by showing that the magnitude of the
antihypersensitivity effect induced by the spinally administered
TRPA1 antagonist was not reduced when the treatment period was
prolonged to a week, which contrasts with the development of
antinociceptive tolerance following prolonged treatment e.g. with mor-
phine (Trang et al., 2015), in which phenomenon spinal TRPA1 may be
partly involved in (Wei et al., 2016). At a dose producing a significant
antihypersensitivity effect, the currently used TRPA1 antagonist has
not influenced locomotor activity in the Rotarod test (Wei et al., 2009)
or in the open-field test (Wei et al., 2012). These earlierfindings indicate
that the TRPA1 antagonist-induced suppression of pain hypersensitivity
may not be explained by action on the motor system.
Prolonged twice daily spinal administrations of a TRPA1 antagonist
or a gap junction decoupler failed to prevent development of hypersen-
sitivity in the present study as indicated by the finding that the baseline
responses to mechanical stimulation assessed before administration of
the last drug dose (i.e., assessed on the seventh treatment day at a
time point when the acute pharmacological effect of the previous drug
dose was over) were not significantly different from those in vehicle-
treated controls, although the first drug doses of the prolonged treat-
ment period were given prior to nerve injury. In contrast, e.g. a single
dose of an N-methyl-D-aspartate antagonist administered systemically
15min prior to but not 15min after spinal nerve ligation has attenuated
development of hypersensitivity indicating a pre-emptive analgesic ef-
fect (Wei and Pertovaara, 1999). On the other hand, repeated systemicadministration of a TRPA1 antagonist has attenuated not only mainte-
nance but also development of baseline hypersensitivity in diabetic
neuropathy (Koivisto et al., 2012). It still remains to be studied whether
repeated systemic (unlike spinal) administrations of a TRPA1 antagonist
or a gap junction blockermight suppress development of the nerve liga-
tion-induced as well as diabetic hypersensitivity.
In the spinal dorsal horn, TRPA1 is expressed on central terminals of
nociceptive primary afferent fibers where it amplifies glutamatergic
transmission (Kosugi et al., 2007). On the other hand, peripheral injury
discharge leads to spinal increase of reactive oxygen species (Park et al.,
2006),which are TRPA1 agonists (Andersson et al., 2008) that potential-
ly contribute to the TRPA1-mediated spinal facilitation of pain. Conse-
quently, blocking the TRPA1 on central terminals of primary afferent
fibers is expected to attenuate pain-related responses providing one al-
though not necessarily the only plausible explanation for the
antihypersensitivity effect following block of the spinal TRPA1 in the
present study.
Astrocytes, a subgroup of glial cells, is another cell type in the ner-
vous system expressing TRPA1 (Shigetomi et al., 2011). Injury-induced
activation of astrocytes is known to contribute to long-termpain though
various actions (Hansson, 2010). In linewith this, earlier studies togeth-
er with the present findings indicate that spinally administered
carbenoxolone, a gap junction blocker inhibiting activated astrocytes,
attenuates neuropathic pain hypersensitivity (Spataro et al., 2004; Roh
et al., 2010;Wang et al., 2014; Yoon et al., 2013). Amongmultiplemech-
anisms through which injury-induced activation of spinal astrocytes
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astroglial D-amino acid oxidase (DAAO) that catalyzes oxidation of D-
amino acids to hydrogen peroxidase (H2O2). This is indicated by the
previous findings that injury induced pain behavior that was associated
with upregulation of DAAO mRNA and increase of DAAO in the SDH,
while knockout of DAAO gene or administration of DAAO inhibitor sup-
pressed pain hypersensitivity in injured or sleep-deprived intact ani-
mals (Chen et al., 2012; Gong et al., 2011; Hopkins et al., 2013; Lu et
al., 2012; Wei et al., 2013; Zhao et al., 2010). It is noteworthy that the
end product of the astrocyte-DAAO pathway, H2O2 is a TRPA1 agonist
(Andersson et al., 2008). Therefore, it may be speculated that H2O2 gen-
erated by activation of the astrocyte-DAAO pathway is among underly-
ing TRPA1-mediated pronociceptive mechanisms in neuropathy
through a direct H2O2-driven action on TRPA1 on central terminals of
primary afferent nerve fibers that leads to amplification of nociceptive
transmission. The finding that a spinally administered gap junction
blocker failed to produce a significant prevention of the TRPA1 ago-
nist-induced hypersensitivity does not support the hypothesis that
H2O2 generated by astroglial DAAO provides a feedforward mechanism
by acting on TRPA1 on astrocytes, thereby upregulating the astrocyte-
DAAO-H2O2 pathway. Thus, neuropathy may have induced activation
of astrocytes, at least partly, through mechanisms that may not involve
TRPA1. This explanation does not exclude the possibility that TRPA1
(e.g. on the central endings of primary afferent nociceptors) is among
final pronociceptive targets in the pronociceptive pathwaydriven by ac-
tivated astrocytes.
The present finding that prolonged as well as acute spinal adminis-
tration of carbenoxolone, a gap junction decoupler that reduces activa-
tion of astrocytes, produced an antihypersensitivity effect is in line with
earlier evidence suggesting that the astrocyte-DAAO-H2O2 pathway
contributes to neuropathic hypersensitivity (Zhao et al., 2010) and
with the hypothesis that at least partly this pathway promotes neuro-
pathic pain due to action on TRPA1. Carbenoxolone as well as
Chembridge-5861528 preferentially suppressed hypersensitivity at an
innocuous stimulus force (2 g), while at the currently used doses
these compounds failed to produce a significant antihypersensitivity ef-
fect at a noxious stimulus force (15 g).
In contrast to the evidence indicating that activation of the astro-
cyte-DAAO pathway promotes pain, there are also studies suggesting
that inhibition of DAAO has a pronociceptive effect (e.g., Dieb and
Hafidi, 2013; Miraucourt et al., 2011; Wake et al., 2001), possibly due
to accumulation of D-serine, an endogenous agonist on the glycine-
binding B site of the pronociceptive N-methyl-D-aspartate receptor
(Schell et al., 1995). In an earlier study, however, inhibition of spinal
DAAO was accompanied by suppression of sustained formalin-induced
pain behavior but not with a significant elevation of spinal D-serine
level (Lu et al., 2012) which finding supports the proposal that spinal
DAAO has pro- rather than antinociceptive action. It remains to be stud-
ied which experimental factors determine whether DAAO enhances or
suppresses pain. Moreover, further studies are needed to assess wheth-
er TRPA1 on oligodendrocytes, a third type of cell in the nervous system
expressing TRPA1 (Hamilton et al., 2016), contributes to the mainte-
nance of neuropathic pain.
Spinal administration of the comparison drug, gabapentin, sup-
pressed effectively (tactile allodynia-like) hypersensitive responses
assessed at an innocuous mechanical stimulus force even after single
treatment which is line with earlier results (Cheng et al., 2000). Previ-
ously, (mechanical hyperalgesia-like) hypersensitive responses evoked
by a noxious stimulus force were only weakly suppressed by acute spi-
nal administration of gabapentin, whereas following a five-day treat-
ment the antihyperalgesic effect of gabapentin was significantly
enhanced (Patel et al., 2001). Partly in linewith this, acute spinal admin-
istration of gabapentin at an antiallodynic dose failed to reducemechan-
ical hyperalgesia in the present study. However, prolongation of the
treatment period by several days failed to enhance the mechanical
antihyperalgesia effect, as described before (Patel et al., 2001).4.2. Expression of TRPA1 mRNA or DAAO mRNA in the DRG and SDH
Studies assessing TRPA1 expression in the dorsal root ganglion
(DRG) following nerve injury have given variable results. In one study,
immunohistochemistry revealed increased TRPA1-like labeling in the
DRG of injured nerve and this was accompanied by an increased per-
centage of DRG neurons responding to a TRPA1 agonist (Ji et al.,
2008). In line with this, increased TRPA1 mRNA has been reported in
the DRG of the injured nerve (Frederick et al., 2007; Ta et al., 2010) or
only in the DRG of the adjacent nerve (Obata et al., 2005). In contrast,
there are also studies reporting only nerve injury-induced downregula-
tion of TRPA1 mRNA (Caspani et al., 2009; Persson et al., 2010; Staaf et
al., 2009) accompanied by a reduced DRG response to a TRPA1 agonist
(Caspani et al., 2009).
In the present study, TRPA1 mRNA was increased in the DRG of SNI
animals of the present study, which finding is in line with the results of
some (Frederick et al., 2007; Michot et al., 2014; Ta et al., 2010; Zhou et
al., 2013) although not all previous studies (Caspani et al., 2009; Persson
et al., 2010; Staaf et al., 2009). While we studied DRG of the injured
nerve, the increase of TRPA1 mRNA might have been more prominent
in the DRG of an adjacent intact nerve as suggested by an earlier inves-
tigation (Obata et al., 2005). No overexpression of TRPA1mRNAwas ob-
served in the SDH, although this finding does not exclude possible
changes in spinal TRPA1 protein expression. Indeed, upregulation of
TRPA1 protein in the SDH has been described in a model of peripheral
nerve injury (Zhang et al., 2014). Spinal treatmentswith a TRPA1 antag-
onist or a gap junction decoupler failed to influence TRPA1 mRNA ex-
pression in the DRG or SDH of SNI animals. However, one should be
cautious with interpretations of these findings since spinally adminis-
tered drugs may have had a limited spread to the DRG. Moreover, the
sensitivity of the assaymight not have been sufficient to detect a poten-
tial drug-induced downregulation of the baseline level of TRPA1 mRNA
in the SDH.
DAAO mRNA was increased in the DRG of SNI animals. Whether or
not the slight upregulation of DAAOmRNA in theDRG is causally related
to neuropathic symptoms, remains to be studied. In the present study,
the spinal drug-induced antihypersensitivity effect may not allow
meaningful comparisons to the DAAO mRNA expression in the DRG,
since spinally administered drugs have a limited access to the DRG. In
the SDH, upregulation of DAAO mRNA has been described in the spinal
nerve ligation-induced model of neuropathy (Zhao et al., 2010) and in
some other experimental conditions such as spinal morphine tolerance
(e.g., Wei et al., 2016). Upregulation of DAAO mRNA was not observed
in the SDH of SNI animals of the present study, unlike earlier in the spi-
nal nerve ligation-induced neuropathy model (Zhao et al., 2010) that
produces amore extensive surgical trauma than SNI, which possibly ex-
plains the difference. As with TRPA1mRNA in the SDH, the sensitivity of
the assay might not have been sufficient to detect a potential drug-in-
duced downregulation of the baseline level of DAAOmRNA in the SDH.4.3. Limitations of the study
Among limitations of the present study is that the assessment of
hypersensitivity was not blinded, although our previous study by
the same experimenter showed that the drug-induced mechanical
antihypersensitivity effect using the same test stimulus procedure in the
rat was of identical magnitude with and without formal blinding (Wei
et al., 2012). Another limitation is that due to the normalization of the
control mRNA data, the control group lacks variability that may have bi-
ased statistical analyses of the mRNA data. Therefore, one should be cau-
tious with interpretations of the differences in mRNA results among the
groups. A potential limitation concerning the antihypersensitivity effect
obtained with the currently used TRPA1 antagonist is that although
Chembridge-5861528 is a highly selective compound (Koivisto and
Pertovaara, 2015), the result had been strengthened if the experiments
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ferent structure.
4.4. Conclusions
In nerve-injured animals, prolonged aswell as acute spinal adminis-
tration of a TRPA1 antagonist effectively attenuatedmaintenance ofme-
chanical hypersensitivity predominantly at an innocuous test stimulus
range. This finding suggests that spinally administered TRPA1 antago-
nists may provide a clinically applicable treatment alternative for atten-
uating tactile allodynia-like hypersensitivity in chronic neuropathy.
Repeated spinal administration of a gap junction decoupler that pre-
sumably inhibited astrocyte activation also proved to be effective in at-
tenuating hypersensitivity to innocuous test stimuli. However, neither
prolonged spinal administration with a TRPA1 antagonist nor with a
gap junction decoupler prevented the development of neuropathic hy-
persensitivity, although prolonged treatments were started as early as
at time of the nerve injury. Upregulations of the TRPA1 and DAAO
mRNA in the DRG but not SDH were associated with the SNI model of
neuropathy, although the potential causal relationships of these minor
upregulations to neuropathic symptoms still remain to be studied.
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